コンテンツにジャンプ
国立がん研究センター 中央病院

トップページ > 診療科のご案内 > 呼吸器内科 > 呼吸器内科について > 業績 > 2013年

2013年

  1. Asahina H, Nokihara H, Yamamoto N, Yamada Y, Tamura Y, Honda K, Seki Y, Tanabe Y, Shimada H, Shi X, Tamura T. Safety and tolerability of AZD8055 in Japanese patients with advanced solid tumors; a dose-finding phase I study. Invest New Drugs 31(3): 677-84, 2013
  1. Funakoshi Y, Fujiwara Y, Kiyota N, Mukohara T, Shimada T, Toyoda M, Imamura Y, Chayahara N, Umezu M, Otsuki N, Nibu K, Minami H. Prediction of glomerular filtration rate in cancer patients by an equation for Japanese estimated glomerular filtration rate. Japanese Journal of Clinical Oncology. 43(3): 271-7, 2013
  1. Ekyalongo RC, Mukohara T, Kataoka Y, Funakoshi Y, Tomioka H, Kiyota N, Fujiwara Y, Minami H. Mechanisms of acquired resistance to insulin-like growth factor 1 receptor inhibitor in MCF-7 breast cancer cell line. Investigational New Drugs. 31(2): 293-303, 2013
  2. Fujiwara Y, Ando Y, Mukohara T, Kiyota N, Chayahara N, Mitsuma A, Inada-Inoue M, Sawaki M, Ilaria R Jr, Kellie Turner P, Funai J, Maeda K, Minami H. A phase I study of tasisulam sodium using an albumin-tailored dose in Japanese patients with advanced solid tumors.. Cancer Chemother Pharmacol 71(4): 991-8, 2013
  1. Nakamichi S, Kubota K, Horinouchi H, Kanda S, Fujiwara Y, Nokihara H, Yamamoto N, Tamura T. Successful EGFR-TKI Rechallenge of Leptomeningeal Carcinomatosis after Gefitinib-induced Interstitial Lung Disease. Japanese Journal of Clinical Oncology 43(4): 422-5, 2013
  1. Kobayashi T, Nishiumi S, Ikeda A, Yoshie T, Sakai A, Matsubara A, Izumi Y, Tsumura H, Tsuda M, Nishisaki H, Hayashi N, Kawano S, Fujiwara Y, Minami H, Takenawa T, Azuma T, Yoshida M. A novel serum metabolomics-based diagnostic approach to pancreatic cancer.. Cancer Epidemiology, Biomarkers & Prevention. 22(4): 571-9, 2013
  1. Funakoshi Y, Mukohara T, Tomioka H, Ekyalongo RC, Kataoka Y, Inui Y, Kawamori Y, Toyoda M, Kiyota N, Fujiwara Y, Minami H. Excessive MET signaling causes acquired resistance and addiction to MET inhibitors in the MKN45 gastric cancer cell line. Investigational New Drugs 31(5): 1158-68, 2013
  1. Fujiwara Y, Chayahara N, Mukohara T, Kiyota N, Tomioka H, Funakoshi Y, Minami H. Hypothyroidism in patients with colorectal carcinoma treated with fluoropyrimidines. Oncology Report 30(4): 1802-6, 2013
  1. Yamamoto, H. Nokihara, Y. Yamada, K. Uenaka, R. Sekiguchi, T. Makiuchi, C.A. Slapak, K.A. Benhadji, T. Tamura, Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 71;1645-1655:2013
  1. Nishio, T. Horai, A. Horiike, H. Nokihara, N. Yamamoto, T. Takahashi, H. Murakami, F. Koizumi, K. Nishio, W. Yusa, N. Koyama, T. Tamura, Phase 1 study of lenvatinib combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer. Br J Cancer 109;538-544: 2013
  1. Kuroda, I. Sekine, M. Sumi, S. Sekii, K. Takahashi, K. Inaba, H. Horinouchi, H. Nokihara, N. Yamamoto, K. Kubota, N. Murakami, M. Morota, H. Mayahara, Y. Ito, T. Tamura, K. Nemoto, J. Itami, Acute radiation esophagitis caused by high-dose involved field radiotherapy with concurrent cisplatin and vinorelbine for stage III non-small cell lung cancer. Technol Cancer Res Treat 12;333-339. 2013
  1. Honda, N. Yamamoto, H. Nokihara, Y. Tamura, H. Asahina, Y. Yamada, S. Suzuki, N. Yamazaki, Y. Ogita, T. Tamura,  Phase I and pharmacokinetic/pharmacodynamic study of RO5126766, a first-in-class dual Raf/MEK inhibitor, in Japanese patients with advanced solid tumors. . Cancer Chemother Pharmacol 72; 577-584: 2013
  1. Goto, M. Nishio, N. Yamamoto, K. Chikamori, T. Hida, M. Maemondo, N. Katakami, T. Kozuki, H. Yoshioka, T. Seto, T. Fukuyama, T. Tamura,  A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC). Lung Cancer 82;109-114. 2013
  1. Horinouchi H, Sekine I, Sumi M, Noda K, Goto K, Mori K, Tamura T. Long-term results of concurrent chemoradiotherapy using cisplatin and vinorelbine for stage III non-small-cell lung cancer.. Cancer Sci. 104(1);:93-7: 2013
  1. Horinouchi H, Kubota K, Itani H, Taniyama TK, Nakamichi S, Wakui H, Kanda S, Nokihara H, Yamamoto N, Sekine I, Tamura T. Short hydration in chemotherapy containing cisplatin (≥75 mg/m2) for patients with lung cancer: a prospective study. Jpn J Clin Oncol 43(11);1105-9: 2013